How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) posted its quarterly earnings data on Monday, March, 2nd. The company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.03.

What other stocks do shareholders of Neon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include VBI Vaccines (VBIV) , Aduro Biotech (ADRO) , Anavex Life Sciences (AVXL) , Occidental Petroleum (OXY) , Pfizer (PFE) , Inovio Pharmaceuticals (INO) , Nabriva Therapeutics (NBRV) , Selecta Biosciences (SELB) , T2 Biosystems (TTOO) and Vaxart (VXRT) .

When did Neon Therapeutics IPO?

Neon Therapeutics (NTGN) raised $101 million in an initial public offering on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

NASDAQ:NTGN

Neon Therapeutics (NTGN) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free NTGN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $3.07
▼
$3.07
50-Day Range: $2.77
▼
$3.07
52-Week Range: $0.88
▼
$6.25

Volume: N/A
Average Volume: 516,108 shs
Market Capitalization: $88.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Neon Therapeutics alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Neon Therapeutics Stock (NASDAQ:NTGN)

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

NTGN Stock News Headlines

April 9, 2024 | seekingalpha.com

BCYC Bicycle Therapeutics plc

February 20, 2024 | investing.com

NTGN_old Historical Data

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

December 22, 2023 | seekingalpha.com

NBCO Neon Bloom, Inc.

March 1, 2023 | theguardian.com

Macbeth review – neon-tinted remix plays like a cinematic thriller

See More Headlines

Receive NTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/02/2020
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:NTGN
CUSIP: N/A
CIK: N/A
Web: www.neontherapeutics.com
Phone: 617-337-4701
Fax: N/A
Employees: 102
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-79,780,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -199.09%
Return on Assets: -137.14%

Debt

Debt-to-Equity Ratio: 0.43
Current Ratio: 1.58
Quick Ratio: 3.00

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 6.14

Miscellaneous

Outstanding Shares: 28,967,000
Free Float: N/A
Market Cap: $88.93 million
Optionable: Not Optionable
Beta: -0.81

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Hugh O'Dowd (Age 54)
Pres, CEO & Director
Dr. Eric S. Lander (Age 62)
Founder & Director
Dr. Yasir B. Al-Wakeel (Age 37)
Chief Financial Officer
Dr. Richard Gaynor (Age 69)
Pres of R&D
Dr. Edward Fritsch Ph.D.
Founder and Chief Technology Officer

Key Competitors

View All Competitors

NTGN Stock Analysis - Frequently Asked Questions

How were Neon Therapeutics' earnings last quarter?: Neon Therapeutics Inc (NASDAQ:NTGN) posted its quarterly earnings data on Monday, March, 2nd. The company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.03.
What other stocks do shareholders of Neon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include VBI Vaccines (VBIV), Aduro Biotech (ADRO), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Pfizer (PFE), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), T2 Biosystems (TTOO) and Vaxart (VXRT).
When did Neon Therapeutics IPO?: Neon Therapeutics (NTGN) raised $101 million in an initial public offering on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

This page (NASDAQ:NTGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Neon Therapeutics (NTGN) Stock Price, News & Analysis

About Neon Therapeutics Stock (NASDAQ:NTGN)

NTGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NTGN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info